Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Longboard Pharmaceuticals Inc
(NQ:
LBPH
)
34.77
+1.41 (+4.24%)
Streaming Delayed Price
Updated: 10:57 AM EDT, Oct 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Longboard Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 04, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
September 26, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome
September 19, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Recap: Longboard Pharmaceuticals Q4 Earnings
March 12, 2024
Via
Benzinga
Starbucks To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Wednesday
September 18, 2024
Via
Benzinga
Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage
September 10, 2024
Truist Securities initiated coverage on Longboard Pharmaceuticals, citing it as a CNS-focused biotech with high-value epilepsy assets.
Via
Benzinga
Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
September 08, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 06, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September
August 28, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress
August 26, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024
August 26, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 02, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 01, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1
July 29, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
July 23, 2024
These three small-cap stocks could deliver hefty returns if the central bank cuts rates.
Via
The Motley Fool
Topics
Economy
Exposures
Interest Rates
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 03, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Top 3 Health Care Stocks That May Crash This Quarter
July 03, 2024
Via
Benzinga
Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
July 01, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
June 10, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 03, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 06, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
LBPH Stock Earnings: Longboard Pharmaceuticals Beats EPS for Q1 2024
May 02, 2024
LBPH stock results show that Longboard Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 02, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
April 03, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
April 02, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
March 12, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
March 01, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 02, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February
February 01, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 26, 2024
Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth quarter, but issued a weak forecast for the first quarter.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.